Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations

A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.

Related Keywords

United States , American , Alessandro Grandini , J Womens Dermatol , International Journal Of Women Dermatology , Image Credit , International Journal , American Journal , Managed Care , Published February , Published January , Alopecia Areata , Jaki Therapy ,